Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer

NCT06858813 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06858813
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06858813 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Recruiting
Start date
April 14, 2025
Completion date
September 30, 2030
Enrollment
232 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular cancer, squamous-cell non-small cell lung cancer